Spending on Hepatitis C Antivirals in the United States, 2009–2015

Pharmacotherapy

Volumn 37, Issue 1, 2017, Pages 65-70

  Suda, Katie J ^a,b   Halbur, Drew J ^b   Hunkler, Robert J ^c   Matusiak, Linda M ^c   Schumock, Glen T ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c IQVIA   (United States)

Author keywords

antiviral; expenditures; Hepatitis C; prescribing practices; withholding treatment

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; DASABUVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG COST; HEPATITIS C; HUMAN; PHARMACY; POSTAL MAIL; RETROSPECTIVE STUDY; UNITED STATES; ECONOMICS; HEALTH CARE COST; TIME FACTOR;

ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DRUG COSTS; HEALTH EXPENDITURES; HEPATITIS C; HUMANS; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 85007155060     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1865     Document Type: Article

References (31)

1. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195–206.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405–16.
3. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207–17.
4. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292–303.
5. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–87.
6. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–65.
7. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA 2014;312:593–4.
8. Brennan TA, Shrank WH. Costs of new treatments for hepatitis C infection—Reply. JAMA 2014;312:2168–9.
9. Owens GM. Revolutionizing treatment outcomes in hepatitis C: managed care implications and considerations—the new and evolving standards of care. Am J Manag Care 2015;21(5 Suppl):S97–105.
10. Owens GM. Hepatitis C: new treatments emerge in 2014 that will have profound implications for payers. Am J Manag Care 2014. Available from http://www.ajmc.com/payer-perspectives/0314/-hepatitis-C-New-treatments-emerge-in-2014-that-will-have-profound-implications-for-payers. Accessed July 30, 2016.
11. Schumock GT, Li EC, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2015. Am J Health Syst Pharm 2015;72:717–36.
12. Editorial Board, New York Times. Costly Hep C Drug for Everybody? Available from http://www.nytimes.com/2015/09/02/opinion/costly-hepatitis-c-drugs-for-everyone.html. Accessed July 30, 2016.
13. Painin E. Costly Hepatitis ‘C’ Drug Makers Face New Fire. The Fiscal Times 2014. Available from http://www.thefiscaltimes.com/2014/12/04/Costly-Hepatitis-C-Drug-Makers-Face-New-Fire. Accessed April 14, 2016.
14. Humer C, Beasley D. Insurers scrutinize drug costs after $84,000 Sovaldi surprise. The Fiscal Times 2014. Available from http://www.thefiscaltimes.com/latestnews/2014/05/28/insurers-scrutinize-drug-costs-after-84000-sovaldi-surprise#sthash.aSwB9XaP.dpuf. Accessed July 30, 2016.
15. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215–23.
16. Lo Re V, Gowda C, Binkley A, et al. Incidence and Determinants of Denial of DAA Treatment for Chronic HCV Infection by Insurance Type During the First 6 months of the Modern HCV Treatment Era [abstract LB-5]. In: American Association for the Study of Liver Diseases Annual Meeting (San Francisco, CA). Alexandria, VA: American Association for the Study of Liver Diseases, 2015:62.
17. Centers for Medicare and Medicaid Services. Assuring Medicaid Beneficiaries Access to Hepatitis C (HCV) Drugs. Available from https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/Rx-Releases/State-Releases/state-rel-172.pdf. Accessed July 30, 2016.
18. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–14.
19. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293–300.
20. Doloresco F, Fominava C, Schumock GT, et al. Projecting future drug expenditures: 2011. Am J Health Syst Pharm 2011;68:921–32.
21. Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures—2012. Am J Health Syst Pharm 2012;69:405–21.
22. Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures in US nonfederal hospitals and clinics—2013. Am J Health Syst Pharm 2013;70:525–39.
23. Schumock GT, Li EC, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2014. Am J Health Syst Pharm 2014;71:482–99.
24. Schumock GT, Li EC, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2016. Am J Health Syst Pharm 2016;73:1058–75.
25. Warehousing of HCV patients reaches new high. PMLive. Available from http://www.pmlive.com/pmhub/healthcare_market_research/109066_the_research_partnership/white_papers_and_resources/warehousing_of_hcv_patients_reaches_new_high. Accessed July 30, 2016.
26. Despite outcry about cost, new HCV therapies likely to save money at VA. US Medicine. Available from http://www.usmedicine.com/agencies/department-of-veterans-affairs/despite-outcry-about-cost-new-hcv-therapies-likely-to-save-money-at-va/. Accessed July 30, 2016.
27. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015;162:397–406.
28. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407–19.
29. Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162:619–29.
30. Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015;41:544–63.
31. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available from http://www.hcvguidelines.org. Accessed April 14, 2016.